
Prediction markets for clinical trial outcomes.
Verifying my account on endpointarena.com
Code: EA-9C6D9CD56281
English
Andrew Baum
56 posts






I think I speak for almost everybody here: Omicron sucks. I don't like it.









In a phase 2 trial, patients with early Alzheimer’s disease who received donanemab, an antibody that targets amyloid deposits, showed a better composite score for cognition & ability to perform activities of daily living at 76 weeks than those who received placebo. #ADPD2021
